Navigation Links
Gen-Probe to Webcast Three Upcoming Investor Presentations
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at three upcoming investor conferences:

  • RBC Capital Markets' Healthcare Conference in New York at 10 a.m. Eastern Time (ET) on March 2.  The Company also will participate in a panel discussion entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
  • Cowen and Company's 31st Annual Healthcare Conference in Boston at 10:15 a.m. ET on March 9.
  • Barclays Capital's 2011 Global Healthcare Conference in Miami at 3:15 p.m. ET on March 16.

  • The presentations and the panel discussion will be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com.  The webcasts will be available for 30 days following the events.

    About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

    Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of
    '/>"/>

    SOURCE Gen-Probe Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
    2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
    3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
    4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
    5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
    6. Gen-Probe to Webcast Two Upcoming Investor Presentations
    7. Neogen Acquires Gen-Probes BioKits Food Safety Business
    8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
    9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
    10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
    11. Gen-Probe to Webcast Two Upcoming Investor Presentations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
    (Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. ... to evaluate the use of udenafil to treat adolescents ... ventricle heart defects. The clinical program will follow protocols ... the Pediatric Heart Network (PHN), a multi-center clinical research ... Institute (NHLBI) of the National Institutes of Health (NIH). ...
    (Date:7/23/2014)... , July 23, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... investigational new drug application ("IND") with respect to ... also announced today that it has received an ... Abuse ("NIDA"), part of the National Institutes of ...
    Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
    ... Orthopedic Group, Inc. (NYSE: HGR ) announced that it continues ... Prosthetics of Texas , Nebraska Orthotic and Prosthetic Services, and Spectrum ... with annual revenues of $14.0 million . , ... "These companies are leaders in their communities ...
    ... June 22 Draeger Medical Canada, Inc. today announced ... System (AIMS) for the Capital District Health Authority and IWK Health Centre ... , , ... of the most comprehensive information technology solution for the safe delivery and ...
    Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 3
    (Date:7/23/2014)... 2014 (HealthDay News) -- Regularly checking the pulse of ... report. "Screening pulse is the method of choice ... 65 who have never had a stroke. Our study ... easy way to identify people who might need more ... author Dr. Bernd Kallmunzer, of Erlangen University in Germany. ...
    (Date:7/23/2014)... Rich Dad® Education, a leader in financial ... yard sale to support Habit for Humanity of Lee and ... proceeds will be donated to Habitat for Humanity. Additionally, all ... to the Habitat for Humanity ReStore thrift store located at ... One of the highlights of the yard sale was a ...
    (Date:7/23/2014)... 23, 2014 Bodybuilding.com, the Internet’s most-visited ... of nutritional supplements, has officially opened the polls for ... , the fastest growing sports nutrition company, is up ... of the Year, Best Tasting Protein of the Year- ... of the year - Whey-HD™, Pre-workout Supplement of the ...
    (Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
    (Date:7/23/2014)... July 23, 2014 (HealthDay News) -- For patients infected ... therapy may help control both viruses, a small study ... to improve treatment strategies for people with the two ... with antiretroviral medications plays an important role in the ... said study leader Dr. Kenneth Sherman, a professor of ...
    Breaking Medicine News(10 mins):Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2
    ... cancer tumours change their hormonal status throughout the course ... treatment for the patient is usually only based on ... biopsy verifications of any relapse will be very important ... Swedish researcher will tell the 2011 European Multidisciplinary Cancer ...
    ... develop bone metastases, and controlling the pain these cause ... III trial of a bisphosphonate drug in these patients ... is as good for pain relief as single dose ... the trial were presented today (Sunday) at the 2011 ...
    ... firm evidence that giving radiotherapy between or during chemotherapy ... the risk of the cancer recurring in the breast ... has minimal adverse side-effects and no detrimental effect on ... the SEquencing of Chemotherapy and Radiotherapy in Adjuvant Breast ...
    ... Melanoma of the eye (ocular or uveal melanoma) frequently spreads ... no effective treatment and patients die within an average of ... live for a year. Now, final results from a phase ... the time patients can live without the disease progressing. ...
    ... FRIDAY, Sept. 23 (HealthDay News) -- Primary care and ... a patient to another doctor, a new study finds. ... after clinical expertise, primary care doctors consider issues such ... to base their decisions on their other patients, experiences ...
    ... Researchers have identified five new genes that play a role ... -- the most common cause of premature death and disability ... The international consortium said their discovery could help scientists predict ... condition. In conducting the study, published online Sept. 22 ...
    Cached Medicine News:Health News:Breast cancer tumor make-up changes through the course of disease 2Health News:Breast cancer tumor make-up changes through the course of disease 3Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 3Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 2Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 3Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 4Health News:Scientists ID More Genes Linked to Heart Disease 2
    Heavy. 7.5 mm curved tip....
    Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm....
    The Storz Protege is an anterior segment unit only....
    The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
    Medicine Products: